Literature DB >> 22350112

The generation of purinome-targeted libraries as a means to diversify ATP-mimetic chemical classes for lead finding.

Eduard R Felder1, Alessandra Badari, Teresa Disingrini, Sergio Mantegani, Christian Orrenius, Nilla Avanzi, Antonella Isacchi, Barbara Salom.   

Abstract

The generation of novel chemotypes in support of our oncology research projects expanded in recent years from a canonical design of kinase-targeted compound libraries to a broader interpretation of purinome-targeted libraries (PTL) addressing the specificity of cancer relevant targets such as kinases and ATPases. Successful screening of structurally diverse ATP-binding targets requires compound libraries covering multiple design elements, which may include phosphate surrogate moieties in ATPase inhibitors or far reaching lipophilic residues stabilizing inactive kinase conformations. Here, we exemplify the design and preparation of drug-like combinatorial libraries and report significantly enhanced screening performance on purinomic targets. We compared overall hit rates of PTL with a simultaneously tested unbiased collection of 200,000 compounds and found consistent superiority of the targeted libraries in all cases. We also analyzed the performance of the largest targeted libraries in comparison with each other and often found striking differences in how a specific target responds to various chemotypes and to whole collections.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22350112     DOI: 10.1007/s11030-012-9361-6

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  28 in total

Review 1.  The protein kinase complement of the human genome.

Authors:  G Manning; D B Whyte; R Martinez; T Hunter; S Sudarsanam
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

Review 2.  ATPases as drug targets: learning from their structure.

Authors:  Patrick Chène
Journal:  Nat Rev Drug Discov       Date:  2002-09       Impact factor: 84.694

3.  Comprehensive analysis of kinase inhibitor selectivity.

Authors:  Mindy I Davis; Jeremy P Hunt; Sanna Herrgard; Pietro Ciceri; Lisa M Wodicka; Gabriel Pallares; Michael Hocker; Daniel K Treiber; Patrick P Zarrinkar
Journal:  Nat Biotechnol       Date:  2011-10-30       Impact factor: 54.908

4.  NMR-based quality control approach for the identification of false positives and false negatives in high throughput screening.

Authors:  Claudio Dalvit; Dannica Caronni; Nicola Mongelli; Marina Veronesi; Anna Vulpetti
Journal:  Curr Drug Discov Technol       Date:  2006-06

5.  Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology.

Authors:  Alex M Aronov; Brian McClain; Cameron Stuver Moody; Mark A Murcko
Journal:  J Med Chem       Date:  2008-02-21       Impact factor: 7.446

6.  A quantitative analysis of kinase inhibitor selectivity.

Authors:  Mazen W Karaman; Sanna Herrgard; Daniel K Treiber; Paul Gallant; Corey E Atteridge; Brian T Campbell; Katrina W Chan; Pietro Ciceri; Mindy I Davis; Philip T Edeen; Raffaella Faraoni; Mark Floyd; Jeremy P Hunt; Daniel J Lockhart; Zdravko V Milanov; Michael J Morrison; Gabriel Pallares; Hitesh K Patel; Stephanie Pritchard; Lisa M Wodicka; Patrick P Zarrinkar
Journal:  Nat Biotechnol       Date:  2008-01       Impact factor: 54.908

7.  Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.

Authors:  Gabriella Traquandi; Marina Ciomei; Dario Ballinari; Elena Casale; Nicoletta Colombo; Valter Croci; Francesco Fiorentini; Antonella Isacchi; Antonio Longo; Ciro Mercurio; Achille Panzeri; Wilma Pastori; Paolo Pevarello; Daniele Volpi; Patrick Roussel; Anna Vulpetti; Maria Gabriella Brasca
Journal:  J Med Chem       Date:  2010-03-11       Impact factor: 7.446

8.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.

Authors:  T Schindler; W Bornmann; P Pellicena; W T Miller; B Clarkson; J Kuriyan
Journal:  Science       Date:  2000-09-15       Impact factor: 47.728

9.  Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase.

Authors:  Riccardo Colombo; Marina Caldarelli; Milena Mennecozzi; Maria Laura Giorgini; Francesco Sola; Paolo Cappella; Claudia Perrera; Stefania Re Depaolini; Luisa Rusconi; Ulisse Cucchi; Nilla Avanzi; Jay Aaron Bertrand; Roberto Tiberio Bossi; Enrico Pesenti; Arturo Galvani; Antonella Isacchi; Francesco Colotta; Daniele Donati; Jürgen Moll
Journal:  Cancer Res       Date:  2010-12-15       Impact factor: 12.701

10.  A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells.

Authors:  Andrew J Massey; Douglas S Williamson; Helen Browne; James B Murray; Pawel Dokurno; Terry Shaw; Alba T Macias; Zoe Daniels; Stephanie Geoffroy; Melanie Dopson; Paul Lavan; Natalia Matassova; Geraint L Francis; Christopher J Graham; Rachel Parsons; Yikang Wang; Antony Padfield; Mike Comer; Martin J Drysdale; Mike Wood
Journal:  Cancer Chemother Pharmacol       Date:  2009-12-13       Impact factor: 3.333

View more
  2 in total

Review 1.  The Potential of Purinergic Signaling to Thwart Viruses Including SARS-CoV-2.

Authors:  Davide Ferrari; Michele Rubini; Jorge S Burns
Journal:  Front Immunol       Date:  2022-06-17       Impact factor: 8.786

2.  The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.

Authors:  Elena Ardini; Roberta Bosotti; Andrea Lombardi Borgia; Cristina De Ponti; Alessio Somaschini; Rosaria Cammarota; Nadia Amboldi; Laura Raddrizzani; Andrea Milani; Paola Magnaghi; Dario Ballinari; Daniele Casero; Fabio Gasparri; Patrizia Banfi; Nilla Avanzi; Maria B Saccardo; Rachele Alzani; Tiziano Bandiera; Eduard Felder; Daniele Donati; Enrico Pesenti; Andrea Sartore-Bianchi; Marcello Gambacorta; Marco A Pierotti; Salvatore Siena; Silvio Veronese; Arturo Galvani; Antonella Isacchi
Journal:  Mol Oncol       Date:  2014-06-12       Impact factor: 6.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.